< CE News
Examining Peanut Allergy Pathophysiology, Immunotherapy Data, and Health Care Utilization
Thu, Feb 28, 2019 10:51 PM UTC
Date: Wednesday, May 1, 2019
Location: Wynn and Encore Hotels
3131 S Las Vegas Boulevard
Las Vegas, Nevada 89109
Time: 7:00 am – 8:30 am
*Breakfast will be available
With peanut allergies affecting about 2.5% of children and 1.2% of the U.S. population overall, it is the most common food allergy in children and a leading cause of allergy-related death. Its prevalence has tripled in a decade, and only 20% of children are expected to outgrow their peanut allergy pointing to a continued increase in peanut allergy-related costs to the healthcare system. Rising incidence of anaphylaxis has triggered an increase in healthcare resource utilization such as emergency department visits and a reduction in the quality of life for a growing number of patients. Most of the efforts to move treatment toward proactively addressing peanut allergies using immunotherapy are focused on desensitization. Specialty pharmacists will be involved in the dispensing of treatments for patients with peanut allergies and can advise patients and caregivers about adverse effects and monitor for adverse events that may discourage utilization. Availability of new immunotherapies also opens the opportunity for pharmacy benefit management professionals to play a proactive role in developing drug benefit management strategies that support the identification of patients and appropriate immunotherapies to reduce healthcare resource utilization as well as help patients control their allergies and improve their quality of life.
- Characterize the prevalence and demographic patterns of peanut allergies in the U.S.
- Explain the pathophysiology and immunological responses in peanut allergies
- Examine emerging immunotherapies and clarify data associated with peanut allergy clinical trial endpoints
- Apply knowledge of novel immunotherapies and desensitization to improve patient quality of care upon integration of peanut allergy immunotherapies into the treatment paradigm
Michael S. Blaiss, MD
Clinical Professor of Pediatrics
Medical College of Georgia
Executive Medical Director
American College of Allergy, Asthma and Immunology
Good Samaritan Health Center of Gwinnett
This activity is supported by an educational grant from Aimmune Therapeutics.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEUs) under the ACPE universal activity number 0290-0000-19-057-L01-P. The activity is available for CE credit for May 1, 2019.
All participants who attended the live symposium need to log on to their Pharmacy Times Continuing Education™ account on www.pharmacytimes.org to complete an online evaluation form and request their credit. Detailed instructions on obtaining credit will be provided at the session. Credit must be requested no later than July 1, 2019.